Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Moderna Inc (NQ: MRNA )

61.95 -1.21 (-1.92%)
Streaming Delayed Price Updated: 1:47 PM EDT, Oct 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,406,771
Open 62.53
Bid (Size) 61.92 (1)
Ask (Size) 61.96 (1)
Prev. Close 63.16
Today's Range 61.55 - 62.97
52wk Range 62.55 - 170.47
Shares Outstanding 384,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Alnylam's Concedes Its Patent Infringement Case Against Moderna's COVID-19 Vaccine
Alnylam Pharmaceuticals has conceded that Moderna's products do not infringe on its patents, as a court ruling determined. Both companies have agreed to dismiss the case without prejudice for possible... 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Is It Time to Buy September's Worst-Performing S&P 500 Stocks?
Could rebounds be in store for these beaten-down stocks? 
Via The Motley Fool
Topics Stocks
Exposures US Equities

Performance

YTD
-44.94%
-44.94%
1 Month
-15.07%
-15.07%
3 Month
-46.58%
-46.58%
6 Month
-38.80%
-38.80%
1 Year
-39.91%
-39.91%

More News

Read More
Abbas Hussain Joins Moderna's Board of Directors
Via ACCESSWIRE
The Covid Era Tech Promises To Reinvent Cancer Treatment
Via Benzinga
Exposures COVID-19
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Here's How Much $100 Invested In Moderna 5 Years Ago Would Be Worth Today
Via Benzinga
Moderna and Cenra Healthcare Enter Joint Agreement to Promote Moderna’s mRNA Respiratory Vaccine Portfolio in Taiwan, Including COVID-19 Vaccines
Via ACCESSWIRE
MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Moderna Announces First Participant Dosed in Pivotal Phase 3 Trial of Investigational mRNA Norovirus Vaccine, mRNA-1403
Via ACCESSWIRE
3 Surprisingly Underrated Stocks to Buy Right Now
Via The Motley Fool
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Moderna, Inc. Investors to Secure Counsel Before Important October 8 Deadline in Securities Class Action – MRNA
From The Rosen Law Firm PA
Via GlobeNewswire
Top 3 Health Care Stocks That May Explode This Month
Via Benzinga
2 Beaten-Down Stocks to Buy and Hold for a Decade
Via The Motley Fool
MODERNA, INC. (NASDAQ: MRNA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Moderna, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Pfizer Advances On Its Cancer Journey
Via Benzinga
Down 13% in 1 Day, Is Moderna Stock in Trouble?
Via The Motley Fool
3 Beaten-Down Stocks Ready for a Comeback
Via MarketBeat
Topics Economy
Exposures Economy
Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks
Via The Motley Fool
Moderna, Inc. REMINDER – MRNA Stockholders Should Contact Robbins LLP for Information About the Moderna, Inc. Class Action and Pending Lead Plaintiff Deadline
From Robbins LLP
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Jim Cramer Labels Moderna A 'Big Disappointment,' But Suggests Doubling Down On Another Pharma Powerhouse
Via Benzinga
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
Via The Motley Fool
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna, Lululemon, XPEL, and Nano Nuclear and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.